Investigational drug · Phase 3
celiprolol
Also called: ACER-002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Vascular Ehlers-Danlos Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "celiprolol"
First trial start
2022
Nov 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "celiprolol", any sponsor or status.
Conditions studied
As listed on its trial records.
- Vascular Ehlers-Danlos Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "celiprolol" as an intervention, largest first.
- Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos SyndromePivotal-lookingRecruiting
Acer Therapeutics Inc.Industry
NCT05432466 · 150 participants (planned) · Start Nov 7, 2022 · Primary completion Mar 1, 2029
Drug: ACER-002 (celiprolol) 200 mg BID; Placebo BID · For: Vascular Ehlers-Danlos Syndrome
Sites: Culver City, California
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00190411 · 54 participants · Start Oct 2003 · Primary completion Apr 2011
Drug: celiprolol; Control · For: EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT; CHROMOSOME 2q31.2 DELETION SYNDROME
- Celiprolol Versus Ditiazem for the Prevention of Postoperative Cardiac Arrythmias in Thoracic SurgeryStatus unknown
Abderrahmane Mami HospitalAcademic, hospital or other
NCT03752931 · 30 participants (planned) · Start Dec 2018 · Primary completion Dec 2019
Drug: Celiprolol; Diltiazem · For: Postoperative Cardiac Complication
Sites: Aryanah, Tunisia
University of DundeeAcademic, hospital or other
NCT02380053 · 10 participants (planned) · Start Jun 7, 2016 · Primary completion Apr 30, 2019
Drug: Bisoprolol; Celiprolol · For: Chronic Obstructive Pulmonary Disease
Sites: Dundee, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Vascular Ehlers-Danlos syndrome: A multidisciplinary clinical framework for early suspicion, emergency-safe management and lifelong care.
Corrao S, Ruggeri MI, Benedetto AD, et al. · J Intern Med 2026
- Clinical Outcomes and Patient Experiences With Celiprolol Therapy in Vascular Ehlers-Danlos Syndrome: The First Non-European Cohort.
Furuhata-Yoshimura M, Yamaguchi T, Kosho T · Am J Med Genet A 2026
- Exploring the Hemorrhagic Manifestations of an Adolescent With Dermatosparaxis-Type Ehlers-Danlos Syndrome: A Case Report.
Balagopal AK, T S S, Selvam A, et al. · Cureus 2026
- Fatal Aortic Rupture at Term Pregnancy Caused by Vascular Ehlers-Danlos Syndrome Diagnosed by Postmortem Genetic Testing Using Formalin-Fixed, Paraffin-Embedded Tissue.
Tadakawa M, Yamaguchi T, Tomita H, et al. · J Obstet Gynaecol Res 2026
- A new microphysiological platform to study the permeation of neuroactive agents across intestinal and brain barriers.
Pavan B, Botti G, Dalpiaz A, et al. · Biofabrication 2026
- Challenges in the Management of Patients with Vascular Ehlers-Danlos Syndrome: Lessons from three Clinical Cases.
Alayasa L, Fiala R, Skafi A, et al. · Eur J Case Rep Intern Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.